Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit)

v3.21.2
Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Other Comprehensive Loss
Beginning balance at Dec. 31, 2019 $ 4,026 $ 4 $ 128,008 $ (123,604) $ (382)
Beginning balance (in shares) at Dec. 31, 2019   39,811,000      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options, net of vesting of restricted shares 96   96    
Exercise of stock options, net of vesting of restricted shares (in shares)   186,000      
Release of restricted stock (in shares)   1,082,000      
Issuance of common stock for payment of board of director fees 1,239   1,239    
Issuance of common stock for payment of legal and board of director fees (in shares)   1,297,000      
Sales of common stock, net of issuance costs 1,342 $ 1 1,341    
Sales of common stock, net of issuance costs (in shares)   1,302,000      
Stock-based compensation expense 3,458   3,458    
Issuance of common stock upon partial conversions of Senior Convertible Note 2,266   2,266    
Issuance of common stock upon partial conversions of Senior Convertible Note (in shares)   1,764,000      
Reacquisition of equity component of Senior Convertible Notes (1,388)   (1,388)    
Equity classified cash conversion feature of Senior Convertible Notes 219   219    
Cumulative translation adjustment (28)       (28)
Net income (loss) (16,041)     (16,041)  
Ending balance at Sep. 30, 2020 (4,811) $ 5 135,239 (139,645) (410)
Ending balance (in shares) at Sep. 30, 2020   45,442,000      
Beginning balance at Jun. 30, 2020 514 $ 4 132,045 (131,078) (457)
Beginning balance (in shares) at Jun. 30, 2020   43,555,000      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options, net of vesting of restricted shares 9   9    
Exercise of stock options, net of vesting of restricted shares (in shares)   33,000      
Release of restricted stock (in shares)   388,000      
Issuance of common stock for payment of board of director fees 225   225    
Issuance of common stock for payment of legal and board of director fees (in shares)   164,000      
Sales of common stock, net of issuance costs 1,342 $ 1 1,341    
Sales of common stock, net of issuance costs (in shares)   1,302,000      
Stock-based compensation expense 1,708   1,708    
Reacquisition of equity component of Senior Convertible Notes (89)   (89)    
Cumulative translation adjustment 47       47
Net income (loss) (8,567)     (8,567)  
Ending balance at Sep. 30, 2020 (4,811) $ 5 135,239 (139,645) (410)
Ending balance (in shares) at Sep. 30, 2020   45,442,000      
Beginning balance at Dec. 31, 2020 (1,979) $ 6 144,156 (145,803) (338)
Beginning balance (in shares) at Dec. 31, 2020   56,371,000      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options, net of vesting of restricted shares $ 71   71    
Exercise of stock options, net of vesting of restricted shares (in shares) 132,396 133,000      
Release of restricted stock (in shares)   1,784,000      
Issuance of common stock for payment of board of director fees $ 66   66    
Issuance of common stock for payment of legal and board of director fees (in shares)   99,000      
Sales of common stock, net of issuance costs 32,708 $ 2 32,706    
Sales of common stock, net of issuance costs (in shares)   17,162,000      
Stock-based compensation expense 3,888   3,888    
Reacquisition of equity component of Senior Convertible Notes 0        
Equity classified cash conversion feature of Senior Convertible Notes 0        
Cumulative translation adjustment (18)       (18)
Net income (loss) (21,711)     (21,711)  
Ending balance at Sep. 30, 2021 13,025 $ 8 180,887 (167,514) (356)
Ending balance (in shares) at Sep. 30, 2021   75,549,000      
Beginning balance at Jun. 30, 2021 9,052 $ 7 177,254 (167,886) (323)
Beginning balance (in shares) at Jun. 30, 2021   72,736,000      
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options, net of vesting of restricted shares 1   1    
Exercise of stock options, net of vesting of restricted shares (in shares)   2,000      
Release of restricted stock (in shares)   772,000      
Sales of common stock, net of issuance costs 2,171 $ 1 2,170    
Sales of common stock, net of issuance costs (in shares)   2,039,000      
Stock-based compensation expense 1,462   1,462    
Cumulative translation adjustment (33)       (33)
Net income (loss) 372     372  
Ending balance at Sep. 30, 2021 $ 13,025 $ 8 $ 180,887 $ (167,514) $ (356)
Ending balance (in shares) at Sep. 30, 2021   75,549,000